PLIAGLIS

This brand name is authorized in Austria, Brazil, Canada, Spain, Hong Kong, Ireland, Poland, Singapore, United States

Active ingredients

The drug PLIAGLIS contains a combination of these active pharmaceutical ingredients (APIs):

1 Lidocaine UNII 98PI200987 - LIDOCAINE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. Read about Lidocaine

2 Tetracaine UNII 0619F35CGV - TETRACAINE

Tetracaine is a local anaesthetic and is believed to act by blocking nerve conduction mainly by inhibiting sodium ion flux across the axon membrane. Read about Tetracaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N01BB52	Lidocaine, combinations	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 510114010005605
Country: CA	Health Products and Food Branch	Identifier(s): 02398028
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 76730
Country: HK	Department of Health Drug Office	Identifier(s): 63840
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100283348
Country: SG	Health Sciences Authority	Identifier(s): 14793P
Country: US	FDA, National Drug Code	Identifier(s): 51672-5305, 73575-009, 73575-010